Physician profile
Jacob Oswald
NPI 1316642598
$1,912.94
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $691 · 2024: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.95 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.16 | 2023-2024 | |
| Janssen Biotech, INC. | $378.13 | 2023-2024 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.35 | 2023-2024 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $155.19 | 2024 | |
| Lilly USA, LLC | $84.75 | 2023-2024 | Omvoh, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $64.33 | 2023-2024 | Entyvio |
| Janssen Scientific Affairs, LLC | $52.77 | 2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $49.03 | 2024 | |
| Genzyme Corporation | $47.77 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.14 | 2024 | Bylvay |
| Regeneron Healthcare Solutions, INC. | $22.46 | 2023 | Dupixent |
| Novo Nordisk INC | $22.11 | 2023 | |
| Intercept Pharmaceuticals, INC. | $21.81 | 2024 | |
| Fresenius Kabi USA, LLC | $21.52 | 2024 | Idacio |
| Qol Medical, LLC | $21.08 | 2023 | Sucraid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.05 | 2023 | Voquezna |
| Sandoz INC. | $21.03 | 2024 | Hyrimoz |
| Vivus LLC | $19.06 | 2024 | Qsymia |
| Pfizer INC. | $19.01 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Oswald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.